Cladribine injection

Generic name: Cladribine (injection)
Brand names: Leustatin Injection
Dosage form: intravenous solution (1 mg/mL)
Drug class: Antimetabolites

Usage of Cladribine injection

Cladribine is a cancer medicine that is used to treat hairy cell leukemia (a type of blood cancer).

Cladribine may also be used for purposes not listed in this medication guide.

Cladribine injection side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Cladribine may cause serious side effects. Call your doctor at once if you have:

numbness, tingling, weakness, or burning pain in your fingers or toes;

loss of movement in any part of your body;

redness, swelling, or itching under your skin;

low blood cell counts--fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath;

kidney problems--little or no urination, swelling in your feet or ankles, feeling tired or short of breath;

signs of infection--fever, chills, cough, chest pain, mouth sores, skin sores, sore throat, trouble breathing; or

signs of tumor cell breakdown--tiredness, weakness, muscle cramps, nausea, vomiting, diarrhea, fast or slow heart rate, tingling in your hands and feet or around your mouth.

Common side effects of cladribine may include:

fever;

nausea, vomiting, diarrhea;

headache, tiredness;

rash;

cough; or

pain, bruising, swelling, or irritation where the medicine was injected.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Cladribine injection

You should not use cladribine if you are allergic to it.

Tell your doctor if you have ever had:

heart problems;

liver or kidney disease; or

weak immune system (caused by disease or by using certain medicine).

Cladribine may harm an unborn baby. Use effective birth control to prevent pregnancy, and tell your doctor if you become pregnant.

You should not breastfeed while using cladribine.

Relate drugs

How to use Cladribine injection

Usual Adult Dose for Hairy Cell Leukemia:

0.09 mg/kg/day by continuous IV infusion for 7 daysAlternate dosing recommendation:-SuBCutaneous bolus injection: 0.14 mg/kg/day subcutaneously for 5 consecutive days -IV infusion: 0.1 mg/kg/day IV for 7 consecutive days -Under certain hematological conditions (e.g., recovery of severe myelosuppression) a small number of patients may require a second cycle and occasionally a third cycle to achieve a stable and prolonged response.Comments:-Physicians should consider delaying or discontinuing therapy if neurotoxicity or renal toxicity occurs.-Consult the individual manufacturer product information for dosing recommendations.Use: For the primary or secondary treatment of patients with Hairy Cell Leukemia (HCL)

Warnings

Cladribine can increase your risk of bleeding or infection. Call your doctor if you have unusual bruising or bleeding, or new signs of infection (fever, chills, cough, chest pain, mouth sores, skin sores, sore throat, trouble breathing).

Very high doses of cladribine injection can cause nerve damage or paralysis that may not be reversible. However, this effect is rare when cladribine is given in recommended doses.

What other drugs will affect Cladribine injection

Cladribine can harm your kidneys, especially if you also use certain medicines for infections, cancer, osteoporosis, organ transplant rejection, bowel disorders, high blood pressure, or pain or arthritis (including Advil, Motrin, and Aleve).

Other drugs may affect cladribine, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Popular FAQ

Over 96 weeks, 81% of patients who took Mavenclad were relapse-free compared to 63% of those who took a placebo. Mavenclad also decreased 3-month progression of disability due to MS when compared to a placebo. Continue reading

No, Mavenclad is not a chemotherapy (cancer) drug. It is an oral purine antimetabolite approved for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Mavenclad tablets are taken by mouth and are given as two yearly treatment courses. Continue reading

Weight gain has not been reported as a side effect with Mavenclad (generic name: cladribine), an oral medicine used for multiple sclerosis (MS). The most common side effects reported with Mavenclad include upper respiratory tract infections, headache and a decrease in white blood cells. Continue reading

Hair loss (alopecia) is an infrequent side effect with Mavenclad. In clinical studies, hair loss occurred in 3% (3 out of every 100) of patients treated with Mavanclad (generic name: cladribine) compared to 1% of patients receiving a placebo (inactive) treatment. Continue reading

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.